Blood based biomarkers for movement disorders.

Area of Science:

• Neurology
• Biomarker Research
• Neurodegenerative Diseases

Background:

• Clinical diagnosis of movement disorders often faces uncertainty, particularly in early stages.
• Existing diagnostic methods lack definitive prognostic capabilities for conditions like Parkinson's disease (PD).

Purpose of the Study:

• To explore the utility of blood-based biomarkers in movement disorder diagnosis and prognosis.
• To assess the potential of p-tau and neurofilament light (NfL) in identifying specific neurodegenerative pathologies and predicting disease progression.

Main Methods:

• Review of current research on blood biomarkers, including p-tau181, p-tau217, and NfL.
• Analysis of biomarker performance in differentiating conditions such as Alzheimer's disease (AD), PD, and Parkinson's plus syndromes (PSP, MSA, CBS).

Main Results:

• p-tau biomarkers may help identify corticobasal syndrome (CBS) linked to AD pathology and predict dementia risk in PD patients.
• Serum/plasma NfL can distinguish PD from Parkinson's plus syndromes and serves as a prognostic indicator for PD and progressive supranuclear palsy (PSP).

Conclusions:

• Blood biomarkers offer valuable tools for enhancing diagnostic accuracy and prognostic assessment in movement disorder clinics.
• Integrating novel protein assays and multi-modal data (clinical, genetic, imaging) is crucial for advancing biomarker application in clinical practice.